New partnership with FourthWall Testing
VANCOUVER, BC, March 31, 2021 / CNW / – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and a world leader in premium psilocybin. Therapeutics and Complementary Diagnostics for Neuroinflammatory Diseases, is pleased to announce that they are establishing a Serotonin Research Center in collaboration with FourthWall Testing Conservatory, Florida.
Fresh Life Sciences Corp. (CNW Group / Fresh Life Sciences Corp.)
NOVA’s neuroinflammatory research program is based on the identification of biomarkers that can be used to confirm the therapeutic efficacy of its proprietary psilocybin-based drug portfolio.
NOVA intends to establish a longitudinal database to support large-scale studies of the microbiome, its relationship to serotonin activity, and behavior metrics related to Autism Spectrum Disorders (ASD). A first focus will be an observational study on people diagnosed with ASD and fragile X syndrome (FXS).
The company recently announced that its proprietary psilocybin drug can modulate fear-like behavior in a valproic acid (VPA) rat autism model. This experiment was carried out in collaboration with the laboratory of Dr. Viviana Trezza, Roma Tre University, Rome, Italy.
“It is NOVA’s intention to identify specific microbes that can contribute to the development of ASD,” stated Marvin S. Hausman MD, Chairman of the Scientific Advisory Board of NOVA. “What’s also most interesting is that 95 percent of the body’s own serotonin is produced by both intestinal cells and bacteria in the human intestine. Only 5 percent is produced in the brain. Serotonin is a key hormone that makes brain cells and other cells possible.” Cells of the nervous system to communicate with each other. Our newly opened Serotonin Research Center, as well as our research partnerships with Microbiome Insights and Thermo Fisher Scientific, give us the opportunity to discover potential biological activities that will lead to the development of ASD and give us the necessary grip to assess the treatment response of autistic children. “
The story goes on
The gut-brain axis is becoming a major topic of discussion at neuroscientific meetings, and recent publications have shown that the trillions of bacteria in the gut could have profound effects on the brain1,2. Studies in mice suggest that infection during pregnancy can stimulate immune cells to produce molecules that travel to the fetus’s brain and induce autism-like behavior3.
There is communication between the enteric (bowel / bowel) nervous system (ENS) and the brain. Dysfunction of the ENS is associated with swallowing problems, excess saliva, mild diarrhea, intestinal obstruction, and inflammatory bowel disease (IBD). ASD and Parkinson’s (PD) are two neurological disorders with signs of ENS involvement, as both are associated with gastrointestinal (bowel) symptoms at the onset of the disease.
A better understanding of ENS involvement in these intestinal and neuroinflammatory diseases could lead to early detection, suggest possible interventions, and be a biological marker of successful treatment response.
The NOVA research center will be able to determine quantitative levels of serotonin in stool, blood and urine samples. Samples from the recently completed VPA rat ASD study in Dr. Trezza are sent to the research center. Stool samples were collected from pregnant rats before and after exposure to VPA and from autistic offspring before and after treatment with psilocybin. The research goal is to develop a deep learning analytical computer program that will analyze the data and identify specific developmental subsets of ASD that may be treated with psilocybin therapy.
“By collecting a large amount of shotgun sequencing data, as well as data on a neurotransmitter believed to be implicated in the etiology of a poorly understood disease like ASD, we can develop new methods of exploring the relationship between the microbiota community to understand serotonin levels and disease severity, “said Dr. Kyle H. Ambert, who is Director of Data Science at Nike, Inc. and a member of NOVA’s Scientific Advisory Board.
The Serotonin Research Center also intends to analyze stool, urine and blood samples from ASD and FXS individuals in The United States and Canada. A clinical study approved by the Institutional Review Board (IRB) has been initiated by NOVA. A listing on ClinicalTrials.gov and the formal start of recruitment in the US will begin in the coming days.
NOVA’s research goal is to shed light on the mechanisms underlying the developmental disorder ASD. Measuring serotonin levels along with other biomarkers can also enable families of autistic individuals to assess disease progression and monitor response to therapeutic interventions.
In addition, the company announces that it has terminated the contract dated December 6, 2017 (the “Agreement”) under which the Company will acquire interests (based on certain milestones achieved) in Just Kush Enterprises Ltd (“Just Kush”), as announced on December 7, 2017.
The company and Kush only have agreed to terminate the contract as it contained several essential provisions that can no longer be fulfilled due to a change in the respective legal regulation. In particular, the agreement contained milestones that must be met in order for material consideration to be made between certain parties and certain other obligations, and those milestones were based on the granting of licenses under the revoked regime for access to cannabis for medical purposes and replaced by the Cannabis Act and the Cannabis Ordinance before these licenses were granted.
Under the termination agreement, purchase proceeds and advances paid by the company under the terms of the agreement will be returned or repaid to the company at a later date under a loan agreement and the company will return all shares in the share capital of Kush only to the original shareholders. Kush only returned 1,250,000 shares in the company for redemption. The company has also entered into a loan repayment agreement Kush only for certain funds made available by the company under the expansion loan plan.
-
Neurogastroenterol Motil 2011 Mar; 23 (3): 255- 64. Reduced fear-like behavior and central neurochemical changes in germ-free mice
KM Neufeld, N Kang, J Beehive, JA Foster -
The microbiome-gut-brain axis: from gut to behavior. Cryan JF, O’Mahony SM. Neurogastroenterol Motil. 2011 Mar; 23 (3): 187-1. 92. doi: 10.1111 / j.1365-2982.2010.01664.x.
-
How gut microbes can fuel brain disorders. Nature briefing. 08February2021
Via FourthWall tests
FourthWall Testing, a subsidiary of Epitome Risk Solutions, is a private laboratory run by industry experts with more than 70 years of experience in drug discovery and development and risk management services for the entertainment and sports industries.
Further information can be found at: https://www.epitomerisk.com/fourthwall-testing/
About Strange Life Sciences Corp.
Nova Mentis Life Science Corp. is a Canada-based biotechnology company and a global leader in the development of diagnostics and psilocybin-based therapeutics for neuroinflammatory diseases. The aim is to diagnose and treat debilitating chronic diseases that have an unmet medical need, such as: B. Autism Spectrum Disorder (ASD) and Fragile X Syndrome.
On behalf of the board
Will Rascan, President and CEO
Fresh Life Sciences Corp.
Phone: 778-819-0244
Toll Free: 1-833-542-5323
Twitter: @novamentislsc
Instagram: @novamentislsc
Facebook: @novamentislsc
Neither the Canadian Stock Exchange nor its Market Regulator (as that term is defined in the Canadian Stock Exchange Policies) accepts responsibility for the adequacy or accuracy of this press release.
This press release contains statements that constitute “forward-looking statements”. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause the actual results, performance or success of Nova Mentis Life Science or developments in the industry to differ materially from the expected results, performance or successes Such forward movements are expressed or implied – telling statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects” . “potential” and similar expressions or that events or conditions “will”, “would”, “may”, “could” or “should” occur.
SOURCE Nova Mentis Life Science Corp.
decision
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/March2021/31/c5504.html